11.   The new user fee act, Feldbaum said, will speed up reviews as well as cut development time and costs for biotechnology and pharmaceutical companies alike.

12.   The successful user fee act, which is set to expire in October, assesses fees on drug companies in return for faster review times at the FDA.

13.   The user fee act, by all accounts a success, will expire at the end of September unless Congress takes action.

14.   Under the so-called user fee act, drug companies pay fees in return for more staff at the FDA and faster reviews.

15.   Under the so-called user fee act, drug companies pay fees to allow the hiring of more staff at the FDA.

16.   Under the user fee act, the drug industry pays fees in return for more staff and faster reviews at the agency.